Approved Tyvaso DPI Label is "Best Case Scenario" - Cowen Bullish on United Therapeutics (UTHR) Following FDA Approval
Tweet Send to a Friend
Cowen analyst Joseph Thome reiterated an Outperform rating and $250.00 price target on United Therapeutics Corp. (NASDAQ: UTHR), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
